162 related articles for article (PubMed ID: 29423069)
1. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.
Dietrich P; Freese K; Mahli A; Thasler WE; Hellerbrand C; Bosserhoff AK
Oncotarget; 2018 Jan; 9(3):3605-3618. PubMed ID: 29423069
[TBL] [Abstract][Full Text] [Related]
2. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of rigosertib, a small molecular RAS signaling disrupter for the treatment of
Zhou X; Xiao Q; Fu D; Zhang H; Tang Y; He J; Hu Y; Kong X; Teng F; Liu X; Yuan Y; Ding K
Cancer Biol Med; 2021 Aug; 19(2):213-28. PubMed ID: 34347396
[TBL] [Abstract][Full Text] [Related]
4. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
5. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
6. PLK1 inhibitors as a new targeted treatment for adrenocortical carcinoma.
Warmington E; Smith G; Chortis V; Liang R; Lippert J; Steinhauer S; Landwehr LS; Hantel C; Kiseljak-Vassiliades K; Wierman ME; Altieri B; Foster PA; Ronchi CL
Endocr Connect; 2024 Jan; 13(1):. PubMed ID: 37992487
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma.
Pellegrino R; Calvisi DF; Ladu S; Ehemann V; Staniscia T; Evert M; Dombrowski F; Schirmacher P; Longerich T
Hepatology; 2010 Mar; 51(3):857-68. PubMed ID: 20112253
[TBL] [Abstract][Full Text] [Related]
8. Lights and Shadows on the Cancer Multi-Target Inhibitor Rigosertib (ON-01910.Na).
Monfort-Vengut A; de Cárcer G
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111716
[TBL] [Abstract][Full Text] [Related]
9. RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation.
Bouhlal H; Ouled-Haddou H; Debuysscher V; Singh AR; Ossart C; Reignier A; Hocini H; Fouquet G; Al Baghami M; Eugenio MS; Nguyen-Khac E; Regimbeau JM; Marcq I
Oncotarget; 2016 Mar; 7(9):9832-43. PubMed ID: 26799423
[TBL] [Abstract][Full Text] [Related]
10. Aspafilioside B induces G2/M cell cycle arrest and apoptosis by up-regulating H-Ras and N-Ras via ERK and p38 MAPK signaling pathways in human hepatoma HepG2 cells.
Liu W; Ning R; Chen RN; Huang XF; Dai QS; Hu JH; Wang YW; Wu LL; Xiong J; Hu G; Guo QL; Yang J; Wang H
Mol Carcinog; 2016 May; 55(5):440-57. PubMed ID: 25683703
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
Wen-Sheng W
Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
13. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors.
Yoshida T; Hisamoto T; Akiba J; Koga H; Nakamura K; Tokunaga Y; Hanada S; Kumemura H; Maeyama M; Harada M; Ogata H; Yano H; Kojiro M; Ueno T; Yoshimura A; Sata M
Oncogene; 2006 Oct; 25(45):6056-66. PubMed ID: 16652141
[TBL] [Abstract][Full Text] [Related]
14. Combined De-Repression of Chemoresistance Associated Mitogen-Activated Protein Kinase 14 and Activating Transcription Factor 2 by Loss of microRNA-622 in Hepatocellular Carcinoma.
Fritz V; Malek L; Gaza A; Wormser L; Appel M; Kremer AE; Thasler WE; Siebler J; Neurath MF; Hellerbrand C; Bosserhoff AK; Dietrich P
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33803354
[TBL] [Abstract][Full Text] [Related]
15. Aberrant Polo-like kinase 1-Cdc25A pathway in metastatic hepatocellular carcinoma.
Wang XQ; Zhu YQ; Lui KS; Cai Q; Lu P; Poon RT
Clin Cancer Res; 2008 Nov; 14(21):6813-20. PubMed ID: 18980975
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
Xu L; Zhu Y; Shao J; Chen M; Yan H; Li G; Zhu Y; Xu Z; Yang B; Luo P; He Q
Br J Cancer; 2017 Apr; 116(8):1027-1036. PubMed ID: 28267710
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis.
Frau M; Feo F; Pascale RM
J Hepatol; 2013 Oct; 59(4):830-41. PubMed ID: 23665184
[TBL] [Abstract][Full Text] [Related]
18. Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication.
Diab A; Foca A; Fusil F; Lahlali T; Jalaguier P; Amirache F; N'Guyen L; Isorce N; Cosset FL; Zoulim F; Andrisani O; Durantel D
Hepatology; 2017 Dec; 66(6):1750-1765. PubMed ID: 28445592
[TBL] [Abstract][Full Text] [Related]
19. High expression of polo-like kinase 1 is associated with early development of hepatocellular carcinoma.
Sun W; Su Q; Cao X; Shang B; Chen A; Yin H; Liu B
Int J Genomics; 2014; 2014():312130. PubMed ID: 25019081
[TBL] [Abstract][Full Text] [Related]
20. Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
Zhang Q; Wei L; Yang H; Yang W; Yang Q; Zhang Z; Wu K; Wu J
Cancer Lett; 2016 Feb; 371(1):107-16. PubMed ID: 26620707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
